PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

About this update from Ptc Therapeutics, Inc.

[{"type":"text","content":"– Full-year 2025 product and royalty revenue of $831M, exceeding guidance –","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"– Cash of $1.95B as of December 31, 2025 –","length":42,"tagName":"p","attribs":{}},{"type":"text","content":"WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.","length":202,"tagName":"p"},{"type":"text","content":""We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs, and strong financial position, we look forward to continued success as we approach cash flow breakeven."","length":376,"tagName":"p"},{"type":"text","content":"Key Corporate Highlights ","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Full-year 2025 product and royalty revenue of $831 million, exceeding guidance","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Global launch of Sephience off to strong start","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Q4 2025 revenue of $92 million, including $81 million revenue in the US and $11 million revenue ex-US","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Sephience total net revenue of $111 million in 2025 since launch","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"946 total patients on commercial therapy worldwide as of December 31, 2025","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"1,134 patient start forms received in the US as of December 31, 2025","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Approval in Japan in December 2025; approval in Brazil in February 2026","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Sephience global footprint expected to increase to 20 to 30 countries by end of 2026","length":84,"tagName":"p"}]}],"tagName...

More updates from Ptc Therapeutics, Inc.